
- Infectious diseases cased by fungi called mycoses
- Many common mycotic infection are superficial and only involve the skin, but fungi may also penetrate the skin causing subcutaneous, cutaneous, and systemic infections






- Eukaryotic organisms
- Have rigid cell wall contain chitin (derivative of glucose) and polysaccharides
- Cell membrane composed of ergosterol



Structure of the chitin molecule




Antifungal Drugs



- The antifungal drugs presently available fall into the following categories Systemic drugs (oral or parenteral) for systemic infections
- → ✓ Amphotericin B
- Flucytosine
- V Azole antifungals
- Cchinocandins
- Oral systemic drugs for mucocutaneous infections - V Griseofulvin
- < Terbenafine
- ~ V Topical azoles

- V Nystatio

- V Terbinafine






For many years, amphotericin B was the only systemic use. While highly effective in many efficacious antifungal drug available for lactone ring of 12 or more atoms)

Naturally occurring polyene macrolide

double bonds; macrolide = containing a large antibiotic (polyene = containing many

- In the last several decades, the relatively the echinocandins (only available for parenteral formulations) and nontoxic azole drugs (both oral and serious infections, it is also quite toxic.
- V/ ~ e chino carding~ gazole parenteral administration) have been Amphotericin 11 JEILI * فحتتجس نست

- Fungi is opportunistic organism which make systemic infection in immunosuppressed individuals (cancer, transplant patients, those debilitated by AIDS, tuberculosis)
- Opportunistic fungi: cryptococcal meningitis or aspergillosis



Cryptoxical meningitis - A coronal section of the brain

Aspergillus pneumonia in lung of deer



2 · Ringworm (). Athlete's foot



3) • Yeast diaper rash


















Amphotericin B

- Pharmacokinetics
- Amphotericin is poorly absorbed from the gastrointestinal tract and is usually administered intravenously (slow intravenous infusion).
- tract and cannot be used for treatment of systemic disease. Oral amphotericin B is thus effective only on fungi within the lumen of the
- intrathecal therapy for certain types of fungal meningitis. The drug is widely distributed in most tissues, but only 2-3% of the blood level is reached in cerebrospinal fluid, thus occasionally necessitating
- Elimination is mainly via hepatic metabolism; the half-life is approximately 2
- A small fraction of the drug is excreted in the urine; dosage modification is necessary only in extreme renal dysfunction.

Amphotericin B

- · Mechanism of action:
- The antifungal action of amphotericin B is due to its of fungal membranes. effects on the permeability and transport properties
- Polyenes are molecules with both hydrophilic and pores membranes, and cause the formation of artificial ipophilic characteristics (ie, they are amphipathic) They bind to ergosterol, a sterol specific to fungal cell

mulia.

- The pores disrupt membrane function, allowing electrolytes (particularly potassium) and small
- Some binding to human membrane sterols does occur, probably accounting for the drug's prominent molecules to leak from the cell, resulting in cell

human membrane

Amphotericin B

- Clinical uses:
- Amphotericin B is one of the most important drugs available for the newer azole drugs for chronic therapy or prevention of relapse. regimens to rapidly reduce fungal burden and then replaced by one of the treatment of systemic mycoses and is often used for initial induction
- It has the widest antifungal spectrum of any agent and remains the drug of choice, or codrug of choice, for most systemic infections caused by Aspergillus, Blastomyces, Candida albicans, Cryptococcus, Histoplasma, and
- Amphotericin B is usually given by slow intravenous infusion at a dosage of 0.5-1 mg/kg/d, but in fungal meningitis intrathecal administration, though dangerous, has been used.
- Local administration of the drug, with minimal toxicity, has been used in treatment of mycotic corneal ulcers and keratitis.




Amphotericin B | ergosterol. affinity for the



- Resistance to amphotericin B occurs if ergosterol binding is impaired, either by:
- decreasing the membrane concentration of ergostero

 by modifying the sterol target molecule to reduce its affinity for the drug.



Amphotericin B

- Adverse Effects:
- 1. Infusion-related reactions are nearly universal and consist of fever, ²chills, muscle spasms, vomiting, headache, and hypotension.
 - They can be ameliorated by slowing the infusion rate or decreasing the daily dose.
- <u>Premedication</u> with antipyretics, antihistamines, meperidine (pethidine), or corticosteroids can be helpful.
- When starting therapy, many clinicians administer a <u>test dose</u> of 1 mg intravenously to scale the severity of the reaction. This can serve as a guide to an initial dosing regimen and premedication strategy.
- **Hypotension:** A shock-like fall in blood pressure accompanied by hypokalemia may occur, <u>requiring potassium supplementation</u>. Care must be exercised in patients taking *digoxin* and other drugs that can cause potassium fluctuations.

Amphotericin B


2. Nephrotoxicity

- Renal damage is the most significant toxic reaction. Renal function usually returns with discontinuation of the drug, but residual damage is likely at high doses.
- Amphotericin B decreases the glomerular filtration rate and causes renal tubular acidosis with magnesium and potassium wasting.
- Anemia may result from decreases in the renal formation of erythropoietin.
- It is common practice to <u>administer normal saline infusions with the</u> <u>daily doses of amphotericin B</u> to reduce renal damage.
- Dose reduction (with lowered toxicity) is possible in some infections when amphotericin B is used with flucytosine.

3. Neurotoxicity

Intrathecal administration of amphotericin B may cause seizures and neurologic damage.

الممسوحة ضوئيا بـ CamScanner



Flucytosine

Clinical uses:

- The antifungal spectrum of 5-FC is narrow; its clinical use at present is confined
- 1. combination therapy with amphotericin B for cryptococcal meningitis
- 2. combination therapy with itraconazole for chromoblastomycosis (subcutaneous


Adverse effects:

- The adverse effects of flucytosine result from metabolism (possibly by intestinal flora) to the toxic antineoplastic compound fluorouracil.
- Bone marrow toxicity with anemia, leukopenia, and thrombocytopenia are the most common adverse effects.

Flucytosine (5-FC) combination

 5-FC is a synthetic pyrimidine often used with amphotericin B for the treatment of systemic mycoses and meningitis caused by Cryptococcus neoformans and Candida albicans.

- · Mechanism of action:
- 5-FC enters fungal cells by cytosine permease.
- Once inside, it is converted to 5-fluorouracil (5-FU) by the enzyme cytosine deaminase.
- Selective toxicity occurs because mammalian cells lack cytosine deaminase.
- Fungi lacking cytosine deaminase are resistant to 5-FC.
- Note: Amphotericin B increases cell permeability, allowing more 5-FC to penetrate the cell. Thus, 5-FC and amphotericin B are synergistic.



* 5 FU+ itraconazole = chromoblastomycosis Tsubcutaneous

آخرہ Azole Antifungal Agents کرہ ماہ ک


- The azoles used for systemic mycoses include ketoconazole, an imidazole, and the triazoles fluconazole, itraconazole, voriconazole, and posaconazole.
- Miconazole, and clotrimazole (an imidazoles) are used only in topical therapy.
- Oral bioavailability is variable (normal gastric acidity is required).
- Fluconazole, itraconazole and voriconazole are available in both oral and intravenous formulations.
- The drugs are distributed to most body tissues, however, drug levels achieved in the CNS are very low (except fluconazole). テルカター カーシー・ Liver metabolism is responsible for the elimination of azole antifungals except
- fluconazole (which is eliminated by the kidneys, largely in unchanged form).

TABLE 48-2 Pharmacologic properties of five systemic azole drugs.

	Water Solubility	Absorption	CSF: Serum Concentration Ratio	t, (hours)	Elimination	Formulations
Ketoconazole	Low	Vanutie	<0.1	7-19	Hepatic	
ltraconazole	Low	Variable	<001	24-42	Hepatic	0.4
Fluconazole	High	High	>0.7	22-31	The state of the s	Oral, IV
Voriconazole	High	High	STATE OF THE PARTY	4	Renai	Cral IV
Posaconazole	Low	High		25	Hepatic	ONN
					Hepatic	Out

Flucytosine (5-FC)

- 1. 5-FU is converted into 5-fluorouridine monophosphate(FUMP), which is phosphorylated further to FUTP. > in hibit m R NA
 - · This is incorporated into RNA, resulting in disruption of protein synthesis.
- 2. 5-FU is also converted to 5-fluorodeoxyuridine monophosphate (fdUMP)
 - fdUMP is a potent inhibitor of thymidylate synthase, thereby depriving the fungi of thymidylic acid, an essential
- Resistance:
- Resistance can occur rapidly if flucytosine is used alone and involves decreased activity of the fungal permeases or




Azole Antifungal Agents

> selectivity Azole Antifungal Agents

Clinical uses

- clinical u

 Ketoconazole was the first oral azole introduced into clinical use. It is distinguished from triazoles by its greater propensity to inhibit mammalian cytochrome P450 enzymes; that is, it is less selective for fungal P450 than are the newer azoles. As a result, systemic ketoconazole use only is only restricted to cases where effective antifungals not available or not tolerated and potential benefits of oral ketoconazole outweigh potential risks.




 It is also used topically in the treatment of seborrheic dermatitis and dandruff.











- The azoles interfere with fungal cell membrane permeability by inhibiting the synthesis of ergosterol.
- These drugs act at the step of 14α-demethylation of lanosterol to ergosterol, which is catalyzed by a fungal cytochrome P450 isozyme.



- With increasing use of azole antifungals, especially for long-term prophylaxis in immunocompromised and neutropenic patients, resistance is occurring.
- Identified mechanisms of resistance include:
 - 1. Mutations in the C-14 α-demethylase gene, which cause decreased azole binding.
 - 2. Additionally, some strains of fungi have developed the ability to pump the azole out of the cell.

Azole Antifungal Agents

Clinical uses

b. Fluconazole -> oral+1V

- Fluconazole is a drug of choice in esophageal and oropharyngeal candidiasis and for most infections caused by Coccidioides.
- A single oral dose usually eradicates vaginal candidiasis.
- Fluconazole is the drug of choice (with amphotericin B) in treatment of active disease due to Cryptococcus neoformans.
- The drug is also equivalent to amphotericin B in candidemia.



* fluconazole = amphotericin = cryptococcus

neoformans

coccidioldes

* fluconazole = amphotericin = for treat candidemia



Azole Antifungal Agents

Pharmacokinetics:

- When ketoconazole or itraconazole are administered orally, they requires gastric acid for dissolution and is absorbed through the intestinal mucosa.
- Drugs that raise gastric pH, such as antacids, or that interfere with gastric acid secretion, such as H2-histamine-receptor blockers and proton-pump inhibitors, impair absorption.
- Administering acidifying agents, such as cola drinks, before taking the drug can improve absorption in patients with achlorhydria.

increases permeability

Azole Antifungal Agents




Adverse Effects:

- Adverse effects of the azoles include vomiting, diarrhea, rash, and sometimes hepatotoxicity, especially in patients with preexisting liver dysfunction.
- Ketoconazole is a notorious inhibitor of hepatic cytochrome P450
 isozymes and may increase the plasma levels of many other drugs,
 including cyclosporine, oral hypoglycemics, phenytoin, and warfarin.
- Inhibition of cytochrome P450 isoforms by ketoconazole interferes with the synthesis of <u>adrenal and gonadal steroids</u> and may lead to gynecomastia, menstrual irregularities, and infertility.
- The other azoles are more selective inhibitors of fungal cytochrome P450. Although they are less likely than ketoconazole to cause endocrine dysfunction, their inhibitory effects on liver drugmetabolizing enzymes have resulted in drug interactions.

Echinocandins

- Echinocandins (Caspofungin, micafungin, and anidulafungin) are the newest class of antifungal agents to be developed.
- Echinocandins are available only in intravenous formulations.
- Echinocandins interfere with the synthesis of the fungal cell wall by inhibiting the synthesis of $\beta(1,3)$ -glucan, leading to lysis and cell death.
- These agents are active against Candida and Aspergillus, but not C neoformans or boascus to mucormycosis.

Echinocandin agents are extremely well tolerated, with minor gastrointestinal side effects and flushing reported infrequently.




Griseofulvin


- Griseofulvin is only use is in the systemic treatment of dermatophytosis.
- It is administered in a microcrystalline form at a dosage of 1 g/d Absorption is improved when it is given with fatty foods.
- Griseofulvin's mechanism of action at the cellular level is unclear, but it is deposited in newly forming skin where it binds to keratin protecting the skin from new infection.
- Because its action is to prevent infection of these new skin structures, griseofulvin must be administered for 2–6 weeks for skin and hair infections to allow the replacement of infected keratin by the resistant structures. Nail infections may require therapy for months to allow regrowth of the new protected nail and is often followed by relapse.
- Griseofulvin has been largely replaced by newer antifungal medications such as itraconazole and terbinafine.

Terbinafine not have * Terbinafine drug-drug interaction

- Terbinafine is available in an oral formulation and is used at a dosage of 250 mg/d. It is used in the treatment of dermatophytoses especially onychomycosis.
- Like griseofulvin, terbinafine is a keratophilic medication.
- Like the azole drugs, it interferes with ergosterol biosynthesis, but rather than interacting with the P450 system, terbinafine inhibits the fungal enzyme squalene epoxidase. This leads to the accumulation of the sterol squalene, which is toxic to the organism.
- One tablet given daily for 12 weeks achieves a cure rate of up to 90% for onychomycosis and is more effective than griseofulvin or itraconazole.
- Adverse effects are rare, consisting primarily of gastrointestinal upset and headache.
- Terbinafine does not seem to affect the P450 system and has demonstrated no significant drug interactions to date.







Topical azoles

- The two azoles most commonly used topically are clotrimazole and miconazole.
- Both are available over-the-counter and are often used tor vulvovaginal candidiasis.
- to nystatin. Oral clotrimazole troches are available for treatment of oral thrush and are a pleasant-tasting alternative
- are rare infections. Absorption is negligible, and adverse effects In cream form, both agents are useful for dermatophytic
- available and useful in the treatment of seborrheic dermatitis. Topical and shampgo forms of ketoconazole are also



mi conazole clotri mazole dermato Phyte = tinea infection terbinatine